However, in our study, among patients in the HER2-low subgroup, those with recurrent metastatic disease had a longer median PFS compared with those with de novo metastases (17.9 vs. 13.4 months) although the difference did not reach statistical significance (p=0.26). This evidence concerns the gene ERBB2 and metastatic neoplasm.